31Mar 2023
Targeting the Epigenetic Roots of Cancer: Menin-KMT2A Inhibitor Emerges as a Leading Candidate

Targeting the Epigenetic Roots of Cancer: Menin-KMT2A Inhibitor Emerges as a Leading Candidate

Acute leukaemias often harbour KMT2A rearrangements or NMP1 mutations, which drive menin-mediated chromatin remodelling and are associated with a poor prognosis. Now, a first-in-human phase I trial has revealed the promising safety and efficacy of the menin–KMT2A interaction inhibitor revumenib in this context.

  • #oncology

Like

Save

Share